PD23-02: Prostate-specific antigen endpoints in the phase 3 PSMAddition study of [177Lu]Lu-PSMA-617 (177Lu-PSMA-617) combined with ADT and ARPI in patients with PSMA-positive (PSMA+) metastatic hormone-sensitive prostate cancer (mHSPC)

PD23-02: Prostate-specific antigen endpoints in the phase 3 PSMAddition study of [177Lu]Lu-PSMA-617 (177Lu-PSMA-617) combined with ADT and ARPI in patients with PSMA-positive (PSMA+) metastatic hormone-sensitive prostate cancer (mHSPC)

Sunday, May 17, 2026 3:38 PM to 3:46 PM · 8 min. (America/New_York)
206
Abstract

Log in

See all the content and easy-to-use features by logging in or registering!